Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06375356 · ClinicalTrials.gov registry record · NA

Stronger: Muscle Strengthening for Menopause

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
96
Enrollment target

NCT06375356: Completed NA study, sponsored by Stanford University.

NCT06375356 is a NA study that has completed, run by Stanford University. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06375356, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target

Study Summary

Menopause is a period of time with increased risk for muscle and bone loss. Very few people strength train regularly at least 2 times per week, and commonly reported barriers include inadequate time and resources, worries of safety, inadequate knowledge base of what moves to do and how to do them. Menopause-aged women may report unique barriers - or perceived facilitators - to strength training. This pilot study will develop and test the feasibility and acceptability of an at-home, band-based, expert-supported strength training intervention.

Primary Outcome

The total number of strength exercises the participant logs is a measure of adherence to the intervention.

Interventions

  • BEHAVIORAL Resistance Training

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2025-06-01
Est. Completion 2026-05-30
Phase NA
Stanford University

1,744 total trials

What the finished NCT06375356 record still lists

NCT06375356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Resistance Training is the first listed.

NCT06375356 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06375356 about?

NCT06375356 is a clinical study titled "Stronger: Muscle Strengthening for Menopause". Menopause is a period of time with increased risk for muscle and bone loss. Very few people strength train regularly at least 2 times per week, and commonly reported barriers include inadequate time and resources, worries of safety, inadequate knowledge base of what moves to do and how to do them. M...

What is the current status of trial NCT06375356?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2025-06-01. Estimated completion is 2026-05-30.

What interventions are being tested in trial NCT06375356?

The interventions under investigation include: Resistance Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT06375356?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06375356's enrollment target sits among peer trials

96 925th of 2000 higher than 1,070 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06375356, the US trial registry maintained by the National Library of Medicine. NCT06375356 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.